← SynDRA
RANOLAZINE
SynDRA canonical compound SYN0006132 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | SCN9A |
|---|
| Mechanism of action | Sodium channel blocker |
|---|
| Indication | chronic stable angina |
|---|
| Disease area | cardiology |
|---|
All known targets
- SCN5A
- SCN9A
- ABCB1
- KCNH2
- PLG
- SCN10A
- SCN4A
- SLC22A2
Mechanisms of action (all sources)
- Sodium channel blocker
- SCN5A BLOCKER
- Sodium channel protein type V alpha subunit blocker
- SCN4A BLOCKER
- Sodium channel protein type IV alpha subunit blocker
- PLG MODULATOR
Drug classes
- Anti-anginal
- Cardiovascular Agents
- Membrane Transport Modulators
- Sodium Channel Blockers
- Cytochrome P450 2D6 Inhibitors
- P-Glycoprotein Inhibitors
- Organic Cation Transporter 2 Inhibitors
- Cytochrome P450 3A Inhibitors
ATC classes
- C01E · OTHER CARDIAC PREPARATIONS
Cross-references
Synonyms
- ranolazine hydrochloride
- ranexa
- renexa
- ranolazine HCl
- Ranolazina
- Aspruzyo
- Ran d
- CVT-303
- NSC-759100
- RS-43285-003
- Aspruzyo sprinkle
- Ranexa
- Ranexa (previously latixa)
- N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)piperazin-1-yl)acetamide
- CVT 303
- (-)-Ranolazine
- Ranolazine (Ranexa)
- Ranolazine 2HCl
- N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide
- CHEBI:87690
- N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide
- C24H33N3O4
- NCGC00015897-02
- DSSTox_RID_80743
- DSSTox_CID_25196
- DSSTox_GSID_45196
- Ran4
- Latixa
- RAN D
- Ranolazine dihydrochloride
- KEG-1295
- RS-43285
- Ranexa (TN)
- Ranexa, Ranolazine
- Ranolazine (USAN/INN)
- Ranolazine extended-release
- Ranolazine/Dronedarone Fixed-Dose Combination
- ASPRUZYO
Reported adverse events
Look up RANOLAZINE in the interactive SynDRA portal →